Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease: An Update

By Nyholm Dag  

Clinical Pharmacokinetics, Vol. 45, Iss. 2, 2006-01 ,pp. : 109-136

Adis International

Access to resources Recommend Favorite

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

By Fulvio Bracco  

CNS Drugs, Vol. 18, Iss. 11, 2004-01 ,pp. : 733-746

Adis International

Access to resources Recommend Favorite

Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease?

By Le W-D.   Jankovic J.  

Drugs & Aging, Vol. 18, Iss. 6, 2001-06 ,pp. : 389-396

Adis International

Access to resources Recommend Favorite

Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson's Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 14, 2012-12 ,pp. : 1556-1564

Bentham Science Publishers

Access to resources Recommend Favorite

Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson's Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study

By Trifirò Gianluca   Mokhles M. Mostafa  

Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. : 159-171

Adis International

Access to resources Recommend Favorite